1. Home
  2. ENHA vs PRME Comparison

ENHA vs PRME Comparison

Compare ENHA & PRME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Enhanced Group Inc. Class A Common Stock

ENHA

Enhanced Group Inc. Class A Common Stock

HOLD

Current Price

$1.09

Market Cap

632.1M

ML Signal

HOLD

Logo Prime Medicine Inc.

PRME

Prime Medicine Inc.

HOLD

Current Price

$3.60

Market Cap

526.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ENHA
PRME
Founded
N/A
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Services-Misc. Amusement & Recreation
Medicinal Chemicals and Botanical Products
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
632.1M
526.0M
IPO Year
2025
2022

Fundamental Metrics

Financial Performance
Metric
ENHA
PRME
Price
$1.09
$3.60
Analyst Decision
Strong Buy
Buy
Analyst Count
3
14
Target Price
$4.00
★ $7.11
AVG Volume (30 Days)
704.2K
★ 4.5M
Earning Date
11-13-2026
11-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 18.18
EPS
N/A
★ N/A
Revenue
N/A
★ $4,632,000.00
Revenue This Year
N/A
$90.65
Revenue Next Year
$168.06
$19.47
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 55.28
52 Week Low
$1.06
$2.67
52 Week High
$4.60
$5.10

Technical Indicators

Market Signals
Indicator
ENHA
PRME
Relative Strength Index (RSI) 34.83 52.12
Support Level $1.06 $2.89
Resistance Level $1.62 $3.64
Average True Range (ATR) 0.15 0.36
MACD -0.01 0.01
Stochastic Oscillator 12.00 50.68

Price Performance

Historical Comparison
ENHA
PRME

About ENHA Enhanced Group Inc. Class A Common Stock

Enhanced Group Inc develops and sells sports and performance-related products intended for use by athletes and consumers. Its offerings focus on products associated with physical performance, health, and recovery. Its two principal offerings include: (i) the Enhanced Games, a live, multi-sport competition platform designed to showcase both "Enhanced" and "Non-Enhanced" athletes pursuing world-record performances under medically supervised conditions; and (ii) Live Enhanced, a direct-to-consumer digital and clinician-guided wellness platform offering evidence-based protocols, supplements, and coaching for consumers seeking to improve health, longevity, and well-being. The majority of the company's revenue is derived from products associated with physical performance, health, and recovery.

About PRME Prime Medicine Inc.

Prime Medicine Inc is a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression. Its program, PM577 for Wilson Disease, is designed to initially correct the H1069Q mutation in the ATP7B gene and is supported by preclinical data showing targeted correction and restoration of copper homeostasis in animal models. In addition, PM647 is being developed for alpha-1 antitrypsin deficiency, or AATD, another liver targeted disease with substantial unmet need.

Share on Social Networks: